Janux Therapeutics (JANX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$1.30 (-1.96%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Janux Therapeutics (JANX)
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Key Insights

Critical company metrics and information
  • Share Price

    $64.99
  • Market Cap

    $3.41 Billion
  • Total Outstanding Shares

    52.48 Million Shares
  • Total Employees

    76
  • Dividend

    No dividend
  • IPO Date

    June 11, 2021
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.januxrx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$327.42 Million
Net Cash Flow From Operating Activities$-36.99 Million
Net Cash Flow From Operating Activities, Continuing$-36.99 Million
Net Cash Flow$9.60 Million
Net Cash Flow From Investing Activities$-280.82 Million
Net Cash Flow, Continuing$9.60 Million
Net Cash Flow From Financing Activities, Continuing$327.42 Million
Net Cash Flow From Investing Activities, Continuing$-280.82 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$-60.54 Million
Costs And Expenses$73.58 Million
Net Income/Loss Available To Common Stockholders, Basic$-60.54 Million
Benefits Costs and Expenses$73.58 Million
Basic Earnings Per Share$1.17
Operating Income/Loss$-85.96 Million
Research and Development$59.82 Million
Income/Loss From Continuing Operations Before Tax$-60.54 Million
Revenues$13.05 Million
Basic Average Shares$53.62 Million
Other Operating Expenses$39.19 Million
Nonoperating Income/Loss$25.43 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$-60.54 Million
Diluted Earnings Per Share$1.17
Diluted Average Shares$53.62 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$99.01 Million
Net Income/Loss$-60.54 Million
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Liabilities$17.17 Million
Liabilities And Equity$695.02 Million
Liabilities$38.91 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Non-current Assets$23.32 Million
Equity$656.10 Million
Noncurrent Assets$28.70 Million
Accounts Payable$2.46 Million
Assets$695.02 Million
Fixed Assets$5.37 Million
Current Assets$666.32 Million
Wages$3.90 Million
Other Current Liabilities$10.82 Million
Noncurrent Liabilities$21.74 Million
Equity Attributable To Parent$656.10 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.